EUVIMEDEUVIMED entdecken
Fallbericht

Successful Treatment of POLD1 Deficiency With HSCT : Report of Two Years' Experience

Sevgi Keles iD, Vedat Uygun iD, Mehmet Ali Karaselek iD, Serkan Küççüktürk iD, Oznur Dogar iD, Gunhal Satırtav iD, Seyma Celikbilek Celik iD, Bahadır Feyzioglu iD, Sukru Guner iD, Ismail Reisli iD, Gülsün Karasu iD, Akif Yeşilipek iD

Pediatric Transplantation · 2026-05 · 30 (5)

DOI: 10.1111/petr.70331 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Pediatric Transplantation, online erschienen am 08.05.2026. Verfasst von Sevgi Keles und 11 weiteren Autor:innen. Beteiligte Einrichtung: Necmettin Erbakan University, Medical Faculty, Division of Pediatric Allergy and Immunology, Konya, Turkey. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Immunologic Deficiency Syndromes. Die Arbeit nennt 14 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

POLD1 defect with immunodeficiency is characterized by T‐cell and NK‐cell lymphopenia, with the patients having a higher susceptibility to herpetic and viral respiratory tract infections. Patients considered for HSCT may be at increased risk of regimen‐related toxicity due to impaired DNA repair. Here, we describe the first case of successful HSCT in a patient with POLD1 deficiency who presented at a relatively older age for immunodeficiency and underwent HSCT despite concerns about DNA‐related toxicity from the conditioning regimen.

Methods

We report the first successful HSCT in an 18‐year‐old woman with POLD1 deficiency who had recurrent pulmonary infections and shingles, and who was IgRT‐dependent. The decision was made to perform HSCT from her matched related donor after informing the family that there was a concern about DNA‐related toxicity following the HSCT procedure.

Results

She underwent HSCT from a matched related donor using a reduced‐intensity regimen (cyclophosphamide, fludarabine, ATG) with bone marrow and peripheral blood as stem cell sources. GVHD prophylaxis included tacrolimus and low‐dose methotrexate. Engraftment occurred promptly, without major complications. Post‐HSCT follow‐up demonstrated improved T‐cell counts and function, and the patient remained well without IgRT.

Conclusion

This first report of HSCT in POLD1 deficiency shows that reduced‐intensity conditioning can achieve engraftment with minimal toxicity, supporting HSCT as a feasible option for these patients. The success of HSCT will be understood more clearly as the cases are presented.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationImmunologic Deficiency SyndromesHumansFemaleAdolescentTransplantation ConditioningTreatment OutcomeImmunosuppressive AgentsGraft vs Host Disease

Stichwörter der Autor:innen

Hematopoetic stem cell transplantationPOLD1 deficiencycombined immune deficiency

Substanzen

Immunosuppressive Agents

Autor:innen und Institutionen

  • Necmettin Erbakan University, Medical Faculty, Division of Pediatric Allergy and Immunology, Konya, Turkey.
  • İstinye University, Faculty of Medicine, MedicalPark Antalya Hospital, Department of Pediatric Bone Marrow Transplantation Unit, Antalya, Turkey.
  • Karamanoğlu Mehmetbey University, Medicine Faculty, Division of Medical Biology, Karaman.
  • Necmettin Erbakan University, Medical Faculty, Division of Ophthalmalogy, Konya, Turkey.
  • Necmettin Erbakan University, Medical Faculty, Division of Microbiology, Konya, Turkey.
  • MedicalPark Göztepe Hospital, Department of Pediatric Bone Marrow Transplantation Unit, İstanbul, Turkey.

ORCID-Profile: Sevgi Keles, Vedat Uygun, Mehmet Ali Karaselek, Serkan Küççüktürk, Oznur Dogar, Gunhal Satırtav, Seyma Celikbilek Celik, Bahadır Feyzioglu, Sukru Guner, Ismail Reisli, Gülsün Karasu, Akif Yeşilipek

Zitieren

APA

Keles, S., Uygun, V., Karaselek, M. A., Küççüktürk, S., Dogar, O., Satırtav, G., Celik, S. C., Feyzioglu, B., Guner, S., Reisli, I., Karasu, G., & Yeşilipek, A. (2026). Successful Treatment of POLD1 Deficiency With HSCT : Report of Two Years' Experience. Pediatric Transplantation, 30(5). https://doi.org/10.1111/petr.70331

Vancouver

Keles S, Uygun V, Karaselek MA, Küççüktürk S, Dogar O, Satırtav G, et al. Successful Treatment of POLD1 Deficiency With HSCT : Report of Two Years' Experience. Pediatric Transplantation. 2026;30(5). doi:10.1111/petr.70331

BibTeX
@article{Keles2026,
  author = {Keles, Sevgi and Uygun, Vedat and Karaselek, Mehmet Ali and Küççüktürk, Serkan and Dogar, Oznur and Satırtav, Gunhal and Celik, Seyma Celikbilek and Feyzioglu, Bahadır and Guner, Sukru and Reisli, Ismail and Karasu, Gülsün and Yeşilipek, Akif},
  title = {Successful Treatment of POLD1 Deficiency With HSCT : Report of Two Years' Experience},
  journal = {Pediatric Transplantation},
  year = {2026},
  volume = {30},
  number = {5},
  doi = {10.1111/petr.70331}
}
Kostenlos starten →